185 related articles for article (PubMed ID: 32134802)
1. PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Kuppermann BD; Patel SS; Boyer DS; Augustin AJ; Freeman WR; Kerr KJ; Guo Q; Schneider S; López FJ;
Retina; 2021 Jan; 41(1):144-155. PubMed ID: 32134802
[TBL] [Abstract][Full Text] [Related]
2. Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration.
Freeman WR; Bandello F; Souied E; Guymer RH; Garg SJ; Chen FK; Rich R; Holz FG; Patel SS; Kim K; López FJ;
Ophthalmol Retina; 2023 Jul; 7(7):573-585. PubMed ID: 36906177
[TBL] [Abstract][Full Text] [Related]
3. A nonhuman primate model of blue light-induced progressive outer retina degeneration showing brimonidine drug delivery system-mediated cyto- and neuroprotection.
Rajagopalan L; Ghosn C; Tamhane M; Almazan A; Andrews-Jones L; Kulkarni A; Christie LA; Burke J; López FJ; Engles M
Exp Eye Res; 2021 Aug; 209():108678. PubMed ID: 34153289
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.
Holz FG; Sadda SR; Busbee B; Chew EY; Mitchell P; Tufail A; Brittain C; Ferrara D; Gray S; Honigberg L; Martin J; Tong B; Ehrlich JS; Bressler NM;
JAMA Ophthalmol; 2018 Jun; 136(6):666-677. PubMed ID: 29801123
[TBL] [Abstract][Full Text] [Related]
5. Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.
Fu DJ; Bagga P; Naik G; Glinton S; Faes L; Liefers B; Lima R; Wignall G; Keane PA; Ioannidou E; Ribeiro Reis AP; McKeown A; Scheibler L; Patel PJ; Moghul I; Pontikos N; Balaskas K
JAMA Ophthalmol; 2024 Jun; 142(6):548-558. PubMed ID: 38722644
[TBL] [Abstract][Full Text] [Related]
6. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
[TBL] [Abstract][Full Text] [Related]
7. Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical Trial.
Rosenfeld PJ; Dugel PU; Holz FG; Heier JS; Pearlman JA; Novack RL; Csaky KG; Koester JM; Gregory JK; Kubota R
Ophthalmology; 2018 Oct; 125(10):1556-1567. PubMed ID: 29716784
[TBL] [Abstract][Full Text] [Related]
8. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS; Lad EM; Holz FG; Rosenfeld PJ; Guymer RH; Boyer D; Grossi F; Baumal CR; Korobelnik JF; Slakter JS; Waheed NK; Metlapally R; Pearce I; Steinle N; Francone AA; Hu A; Lally DR; Deschatelets P; Francois C; Bliss C; Staurenghi G; Monés J; Singh RP; Ribeiro R; Wykoff CC;
Lancet; 2023 Oct; 402(10411):1434-1448. PubMed ID: 37865470
[TBL] [Abstract][Full Text] [Related]
9. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.
Jaffe GJ; Westby K; Csaky KG; Monés J; Pearlman JA; Patel SS; Joondeph BC; Randolph J; Masonson H; Rezaei KA
Ophthalmology; 2021 Apr; 128(4):576-586. PubMed ID: 32882310
[TBL] [Abstract][Full Text] [Related]
10. Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials.
Heier JS; Pieramici D; Chakravarthy U; Patel SS; Gupta S; Lotery A; Lad EM; Silverman D; Henry EC; Anderesi M; Tschosik EA; Gray S; Ferrara D; Guymer R;
Ophthalmol Retina; 2020 Jul; 4(7):673-688. PubMed ID: 32199866
[TBL] [Abstract][Full Text] [Related]
11. Randomized Trial to Evaluate Tandospirone in Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GATE Study.
Jaffe GJ; Schmitz-Valckenberg S; Boyer D; Heier J; Wolf-Schnurrbusch U; Staurenghi G; Schmidt-Erfurth U; Holz FG
Am J Ophthalmol; 2015 Dec; 160(6):1226-34. PubMed ID: 26310670
[TBL] [Abstract][Full Text] [Related]
12. SYSTEMIC MEDICATION USE AND THE INCIDENCE AND GROWTH OF GEOGRAPHIC ATROPHY IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.
Song D; Hua P; VanderBeek BL; Dunaief JL; Grunwald JE; Daniel E; Maguire MG; Martin DF; Ying GS;
Retina; 2021 Jul; 41(7):1455-1462. PubMed ID: 33332813
[TBL] [Abstract][Full Text] [Related]
13. Effect of Human Central Nervous System Stem Cell Subretinal Transplantation on Progression of Geographic Atrophy Secondary to Nonneovascular Age-Related Macular Degeneration.
Nittala MG; Uji A; Velaga SB; Hariri AH; Naor J; Birch DG; Spencer R; Leng T; Capela A; Tsukamoto A; Ip M; Sadda SR
Ophthalmol Retina; 2021 Jan; 5(1):32-40. PubMed ID: 32562884
[TBL] [Abstract][Full Text] [Related]
14. Relationship of Topographic Distribution of Geographic Atrophy to Visual Acuity in Nonexudative Age-Related Macular Degeneration.
Shen LL; Sun M; Ahluwalia A; Young BK; Park MM; Toth CA; Lad EM; Del Priore LV
Ophthalmol Retina; 2021 Aug; 5(8):761-774. PubMed ID: 33212271
[TBL] [Abstract][Full Text] [Related]
15. Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration.
Pfau M; von der Emde L; de Sisternes L; Hallak JA; Leng T; Schmitz-Valckenberg S; Holz FG; Fleckenstein M; Rubin DL
JAMA Ophthalmol; 2020 Oct; 138(10):1026-1034. PubMed ID: 32789526
[TBL] [Abstract][Full Text] [Related]
16. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Patel SS; Lally DR; Hsu J; Wykoff CC; Eichenbaum D; Heier JS; Jaffe GJ; Westby K; Desai D; Zhu L; Khanani AM
Eye (Lond); 2023 Dec; 37(17):3551-3557. PubMed ID: 36964259
[TBL] [Abstract][Full Text] [Related]
17. Orally Administered Alpha Lipoic Acid as a Treatment for Geographic Atrophy: A Randomized Clinical Trial.
Kim BJ; Hunter A; Brucker AJ; Hahn P; Gehrs K; Patel A; Edwards AO; Li Y; Khurana RN; Nissim I; Daniel E; Grunwald J; Ying GS; Pistilli M; Maguire MG; Dunaief JL
Ophthalmol Retina; 2020 Sep; 4(9):889-898. PubMed ID: 32418846
[TBL] [Abstract][Full Text] [Related]
18. Increased Fundus Autofluorescence and Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration: The GAIN Study.
Biarnés M; Arias L; Alonso J; Garcia M; Hijano M; Rodríguez A; Serrano A; Badal J; Muhtaseb H; Verdaguer P; Monés J
Am J Ophthalmol; 2015 Aug; 160(2):345-353.e5. PubMed ID: 25982972
[TBL] [Abstract][Full Text] [Related]
19. Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration: Results from the Prospective Proxima A and B Clinical Trials.
Holekamp N; Wykoff CC; Schmitz-Valckenberg S; Monés J; Souied EH; Lin H; Rabena MD; Cantrell RA; Henry EC; Tang F; Swaminathan B; Martin J; Ferrara D; Staurenghi G
Ophthalmology; 2020 Jun; 127(6):769-783. PubMed ID: 32081489
[TBL] [Abstract][Full Text] [Related]
20. Progression of Unifocal versus Multifocal Geographic Atrophy in Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.
Shen LL; Sun M; Grossetta Nardini HK; Del Priore LV
Ophthalmol Retina; 2020 Sep; 4(9):899-910. PubMed ID: 32423772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
